Smith & Nephew SNATS (NYSE:SNN) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Smith & Nephew SNATS (NYSE:SNN) from a hold rating to a buy rating in a research note published on Sunday morning,Wall Street Zen reports.

Several other research analysts have also commented on SNN. Barclays lowered shares of Smith & Nephew SNATS from an “equal weight” rating to an “underweight” rating in a research note on Wednesday, August 5th. BTIG Research started coverage on shares of Smith & Nephew SNATS in a research note on Monday, August 31st. They issued a “neutral” rating on the stock. Zacks Research upgraded shares of Smith & Nephew SNATS from a “strong sell” rating to a “hold” rating in a report on Tuesday, September 8th. Weiss Ratings raised shares of Smith & Nephew SNATS from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, September 4th. Finally, Morgan Stanley downgraded shares of Smith & Nephew SNATS from an “overweight” rating to an “equal weight” rating in a report on Wednesday, September 2nd. One analyst has rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $31.91.

Smith & Nephew SNATS Stock Performance

Shares of Smith & Nephew SNATS stock opened at $28.01 on Friday. The company has a current ratio of 2.14, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62. The stock has a 50 day moving average price of $29.84 and a 200-day moving average price of $31.02. Smith & Nephew SNATS has a one year low of $27.23 and a one year high of $37.64.

Smith & Nephew SNATS Dividend Announcement

The firm also recently disclosed a dividend, which will be paid on Friday, November 6th. Shareholders of record on Friday, October 2nd will be given a $0.312 dividend. This represents a yield of 205.0%. The ex-dividend date of this dividend is Friday, October 2nd.

Institutional Trading of Smith & Nephew SNATS

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. purchased a new stake in shares of Smith & Nephew SNATS during the second quarter valued at $505,323,000. River Road Asset Management LLC increased its stake in Smith & Nephew SNATS by 13.8% in the 4th quarter. River Road Asset Management LLC now owns 3,169,644 shares of the medical equipment provider’s stock worth $103,996,000 after buying an additional 384,926 shares during the period. Bank of America Corp DE purchased a new position in Smith & Nephew SNATS in the 2nd quarter worth about $97,223,000. Bank of New York Mellon Corp bought a new stake in Smith & Nephew SNATS during the 2nd quarter valued at about $89,325,000. Finally, Caisse de depot et placement du Quebec bought a new stake in Smith & Nephew SNATS during the 2nd quarter valued at about $64,186,000. Hedge funds and other institutional investors own 25.64% of the company’s stock.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company headquartered in the United Kingdom. Founded in 1856 by Thomas James Smith in Hull, the company initially operated as a pharmacy business before expanding into healthcare products and medical devices.

The company develops and manufactures technologies used in orthopaedic reconstruction, sports medicine, and advanced wound management. Its products include joint replacement systems, trauma and extremities devices, arthroscopic equipment, surgical repair technologies, wound dressings, negative-pressure wound therapy systems, and other products designed to support tissue healing and surgical care.

Smith & Nephew serves hospitals, healthcare professionals, and patients in markets around the world.